AZN Jan 2026 110.000 call
| Previous Close | 1.2800 |
| Open | 1.2800 |
| Bid | 0.9900 |
| Ask | 1.2600 |
| Strike | 110.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 1.2800 - 1.2800 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 330 |
Business WireFLUMIST approved for self-administration in the US
WILMINGTON, Del., September 20, 2024--FLUMIST® has been approved in the US as the only self-administered influenza vaccine. FLUMIST, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or administered by a parent/caregiver to individuals 2-17 years of age.1
ZacksPharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.
ReutersUS FDA approves AstraZeneca's self-administered nasal spray flu vaccine
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said. The flu is a common and contagious respiratory disease caused by influenza viruses that typically circulates in the U.S. during the fall and winter. AstraZeneca plans to make the vaccine available through a third-party online pharmacy.
